中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
10期
16-18
,共3页
阿尔茨海默病%美金刚%石杉碱甲
阿爾茨海默病%美金剛%石杉堿甲
아이자해묵병%미금강%석삼감갑
Alzheimer disease%Memantine%Huperzine A
目的 观察石杉碱甲联合美金刚治疗阿尔茨海默病(AD)的临床疗效及安全性.方法 65例AD患者按照入院顺序随机分为治疗组33例和对照组32例,对照组给予美金刚治疗,治疗组给予石杉碱甲和美金刚联合治疗.观察比较两组的临床疗效.结果 治疗组患者治疗后24周简易精神状态量表评分显著高于对照组[(17.9±1.8)分比(16.2±1.2)分,P＜ 0.05],AD评估量表的认知量表评分显著低于对照组[(19.9±4.8)分比(22.2±5.2)分,P＜0.05]；治疗组患者治疗后24周血清超氧化物歧化酶水平显著高于对照组[(102.4±2.3) U/L比(95.4 +7.6) U/L,P＜ 0.05],神经元特异性烯醇化酶水平显著低于对照组[(6.3±1.2) μg/L比(7.4+ 1.4) μg/L,P＜ 0.05].治疗期间,两组患者均未发生严重不良反应.结论 石杉碱甲和美金刚合用具有协同作用,两者联合治疗AD疗效显著,安全可靠.
目的 觀察石杉堿甲聯閤美金剛治療阿爾茨海默病(AD)的臨床療效及安全性.方法 65例AD患者按照入院順序隨機分為治療組33例和對照組32例,對照組給予美金剛治療,治療組給予石杉堿甲和美金剛聯閤治療.觀察比較兩組的臨床療效.結果 治療組患者治療後24週簡易精神狀態量錶評分顯著高于對照組[(17.9±1.8)分比(16.2±1.2)分,P＜ 0.05],AD評估量錶的認知量錶評分顯著低于對照組[(19.9±4.8)分比(22.2±5.2)分,P＜0.05]；治療組患者治療後24週血清超氧化物歧化酶水平顯著高于對照組[(102.4±2.3) U/L比(95.4 +7.6) U/L,P＜ 0.05],神經元特異性烯醇化酶水平顯著低于對照組[(6.3±1.2) μg/L比(7.4+ 1.4) μg/L,P＜ 0.05].治療期間,兩組患者均未髮生嚴重不良反應.結論 石杉堿甲和美金剛閤用具有協同作用,兩者聯閤治療AD療效顯著,安全可靠.
목적 관찰석삼감갑연합미금강치료아이자해묵병(AD)적림상료효급안전성.방법 65례AD환자안조입원순서수궤분위치료조33례화대조조32례,대조조급여미금강치료,치료조급여석삼감갑화미금강연합치료.관찰비교량조적림상료효.결과 치료조환자치료후24주간역정신상태량표평분현저고우대조조[(17.9±1.8)분비(16.2±1.2)분,P＜ 0.05],AD평고량표적인지량표평분현저저우대조조[(19.9±4.8)분비(22.2±5.2)분,P＜0.05]；치료조환자치료후24주혈청초양화물기화매수평현저고우대조조[(102.4±2.3) U/L비(95.4 +7.6) U/L,P＜ 0.05],신경원특이성희순화매수평현저저우대조조[(6.3±1.2) μg/L비(7.4+ 1.4) μg/L,P＜ 0.05].치료기간,량조환자균미발생엄중불량반응.결론 석삼감갑화미금강합용구유협동작용,량자연합치료AD료효현저,안전가고.
Objective To observe the efficacy and safety of huperzine A combined with memantine in patients with Alzheimer disease (AD).Methods Sixty-five cases of AD were randomly divided into control group(32 cases) and treatment group(33 cases) by order of admission.The patients in control group were given memantine.The patients in treatment group were given huperzine A combined with memantine.The efficacy and safety was observed and compared between two groups.Results The mini-mental state examination score after treatment of 24 weeks in treatment group was higher than that in control group [(17.9 ± 1.8) scores vs.(16.2 ± 1.2) scores,P ＜ 0.05].The AD assessment scale of cognitive scale score after treatment of 24 weeks in treatment group was lower than that in control group [(19.9 + 4.8) scores vs.(22.2 ± 5.2) scores,P ＜ 0.05].The superoxide dismutase level after treatment of 24 weeks in treatment group was higher than that in control group [(102.4 ± 2.3) U/L vs.(95.4 ± 7.6) U/L,P ＜ 0.05].The neuron-specific enolase level after treatment of 24 weeks in treatment group was lower than that in control group [(6.3 ± 1.2)μ g/L vs.(7.4 + 1.4)μ g/L,P ＜ 0.05].During treatment,patients showed no serious adverse reactions.Conclusion Huperzine A and memantine has synergistic effects,the combined treatment in AD is safe and reliable.
